Q32 Bio launched an underwritten public offering of USD 200 million in common stock, including pre-funded warrants in lieu of shares for some investors.
Underwriters received a 30-day option to buy up to an additional USD 30 million of common stock.
Proceeds earmarked for working capital, including R&D and advancing bempikibart into future clinical trials.
QTTB•
